Combination Drug Shows Promise for Treating Alzheimer's-Associated Agitation

A combination of deudextromethorphan hydrobromide and quinidine sulfate (AVP-786; Avanir Pharmaceuticals, Alisa Viejo, CA) is being studied as potential treatment of moderate-to-severe agitation in patients with Alzheimer's dementia (AD) (NCT03393520). In preliminary data, patients treated with 1 of the 2 test doses of the combination had less agitation than those given placebo. Agitation was measured with the Cohen-Mansfield Agitation Inventory.    

In this 12-week phase 3 trial, 410 patients with AD, age 50 to 90, were randomly assigned to receive placebo or 1 of 2 different doses of the combination for 6 weeks. After this initial period, those who had been receiving either dose of the drug continued taking it for another 6 weeks. 

"These initial data from the first phase 3 study are encouraging and we look forward to continuing to evaluate AVP-786 for the treatment of moderate-to-severe agitation in patients with AD as the clinical program progresses," said Sanjay Dubé, MD, vice president, research & development, head of clinical development & scientific strategy, Avanir Pharmaceutical. 

The combination therapy is also being investigated in patients with negative symptoms of schizophrenia and neurobehavioral disinhibition in traumatic brain injury.

FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MS

Previous News Article

FDA Clears External Craniostimulation Device for Treatment of Insomnia, Anxiety, and Depression

Next News Article
This Month's Issue
Frontotemporal Dementias

Ryan Taylor, MD; and Elizabeth Finger, MD

Neuropsychiatric Aspects of Alzheimer’s Disease

Zahra Goodarzi, BHSc (Hon), MD, MSc, FRCPC; and Zahinoor Ismail, MD, FRCPC